Icotinib (a tyrosine kinase inhibitor that selectively targets EGFR) combined with bevacizumab has a stronger inhibitory effect on NSCLC growth in vivo than single target drugs without additional side effects (Jiang et al. 2022). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.